Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 0%
- Matching filter
- 2
F·Filter
Reset allT2·Peer-secondary literature
Peer-reviewed reviews and cohort/observational work — context, not bedrock.
2 sources
- 2021Opinionmoderate
The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers
Wakabayashi H, Arai H, Inui A · Journal of Cachexia, Sarcopenia and Muscle
Anamorelin received Japanese PMDA approval on 11 December 2020 for cancer cachexia in four indications — the first regulatory approval for cancer cachexia globally and the first GHSR-1a-agonist approval for a muscle-wasting indication, on essentially the same data the EMA had rejected in 2017.
- 2016Opinionmoderate
Welcome to the ICD-10 code for sarcopenia
Anker SD, Morley JE, von Haehling S · Journal of Cachexia, Sarcopenia and Muscle
The October 2016 assignment of ICD-10-CM code M62.84 separated sarcopenia from cachexia, disuse atrophy, and inflammatory myopathy — the bureaucratic act that formalized sarcopenia as a discrete clinical entity rather than an aspect of frailty or aging in general.